Imunon, Inc. (Nasdaq: IMNN) announced that new data on its IMNN-001 immunotherapy candidate for advanced ovarian cancer will be featured in a poster presentation at the inaugural American Association for Cancer Research Conference on Drug Discovery and Development (AACR D3), held July 21-24, 2026 in Boston, Massachusetts.

The presentation covers translational and clinical data from Imunon's Phase 2 OVATION-2 study, a randomized, controlled trial in 112 patients with newly diagnosed advanced ovarian cancer. The poster reports that IMNN-001 combined with neoadjuvant/adjuvant chemotherapy was associated with a numerical increase in median overall survival of more than 13 months compared to chemotherapy alone (40.5 vs. 27.6 months). Imunon separately announced that final trial results showed a 14.7-month increase in median overall survival (45.1 vs. 30.4 months).

Translational analyses from the trial showed that IMNN-001 enhanced CD8+/Treg and CD8+/CD4+ cell ratios in patients' tumors and tumor microenvironment. No cytokine release syndrome or higher incidence of immune-related events was observed in the IMNN-001 arm of the study.

IMNN-001 is a DNA-based agent using Imunon's TheraPlas platform, designed to produce interleukin-12 (IL-12) locally at the tumor site. The company states this approach differs from systemic recombinant IL-12 administration by aiming for durable, localized IL-12 production.

The OVATION-2 findings are intended to support Imunon's ongoing Phase 3 OVATION-3 trial, which the company says is designed to confirm the safety and survival benefit of IMNN-001 in frontline advanced ovarian cancer, with a potential biologics license application filing if successful.

"Being selected to present at the inaugural AACR D3 meeting is an important recognition of IMUNON's platform and our team's work in ovarian cancer," said Stacy Lindborg, Ph.D., president and chief executive officer of Imunon.